Herbal Medicine in the Treatment of Ulcerative Colitis
Ulcerative colitis (UC) is a refractory, chronic, and nonspecific disease occurred usually in the rectum and the entire colon. The etiopathology is probably related to dysregulation of the mucosal immune response toward the resident bacterial flora together with genetic and environmental factors. Several types of medications are used to control the inflammation or reduce symptoms. Herbal medicine includes a wide range of practices and therapies outside the realms of conventional Western medicine. However, there are limited controlled evidences indicating the efficacy of traditional Chinese medicines, such as aloe vera gel, wheat grass juice, Boswellia serrata, and bovine colostrum enemas in the treatment of UC. Although herbal medicines are not devoid of risk, they could still be safer than synthetic drugs. The potential benefits of herbal medicine could lie in their high acceptance by patients, efficacy, relative safety, and relatively low cost. Patients worldwide seem to have adopted herbal medicine in a major way, and the efficacy of herbal medicine has been tested in hundreds of clinical trials in the management of UC. The evidences on herbal medicine are incomplete, complex, and confusing, and certainly associated with both risks and benefits. There is a need for further controlled clinical trials of the potential efficacy of herbal medicine approaches in the treatment of UC, together with enhanced legislation to maximize their quality and safety.
Keywords: Herbal medicine, inflammatory bowel disease, therapy, ulcerative colitis
Ulcerative colitis (UC) and Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are chronic inflammatory conditions of the gastrointestinal (GI) tract. Although the etiology remains largely unknown, it has been suggested that a combination of genetic susceptibility factors and the activation of the mucosal immune system in response to luminal commensal bacterial antigens along with persistent pathologic cytokine production contributes to the initiation and chronification of IBD.[1–3] The incidence of UC is approximately 10–20 per 105 per year with a reported prevalence of 100–200 per 105 in Western countries.[4–6] However, UC in China has some differences in clinical characteristics, and a population-based epidemiologic study is required to determine the prevalence and incidence. The number of UC patients has increased significantly in the past 10 years in China, lesions were commonly located to the left side colon, males and females were nearly equally affected, no positive relationship was found between smoking and severity of the disease, and familial relatives were rarely involved. Evidences have shown that poor adherence is an important barrier to successful management of the patients with UC. Only 40%–60% of UC patients who were newly diagnosed or had longstanding disease are adherent to therapy.[9–11] Therefore, improving medication adherence has become one of the most important steps in the effective management of the disease.
To date, several medicines have been used in the treatment of UC, such as 5-aminosalicylate, azathioprine, 6-mecaptopurine, cyclosporine, and antitumor necrosis factor monoclonal antibody. The primary aims of medical therapy for patients with UC are directed at inducing and then maintaining remission of symptoms and mucosal inflammation to provide an improved quality of life with the least amount of steroid exposure. In recent years, herbal medicines have been used in the treatment of UC and shown to be effective in the clinic. In this review, we survey the current knowledge of the herbal therapy or traditional Chinese medicine (TCM) for the treatment of patients with UC, and discuss recent progress in their role in disease prevention.
The term “herb” is derived from the Latin word herba meaning “grass.” The term has been applied to plants of which the leaves, stems, or fruit are used for food, for medicines, or for their scent or flavor. Herbal medicine refers to folk and traditional medicinal practice based on the use of plants and plant extracts for the treatment of medical conditions. The use of herbs to treat diseases is almost universal among native people. A number of traditions have come to dominate the practice of herbal medicine in the West at the end of the twentieth century. Herbal medicine is one of the most common TCM modalities. It has been estimated that 28.9% of US adults regularly use one or more TCM therapies, 9.6%–12.1% of which are in the form of herbal products. Recent studies have indicated that the percentage of adults using TCM therapies for their GI symptoms ranges from 20% to 26%, but patients with functional GI disorders are more likely to make use of them, as are those with chronic GI conditions.[13,14]
The use of complementary medicine among patients with IBD, particularly in the form of herbal therapies, is widespread in the Western world as well as in many Asian countries including China and India. It seems that the use is continuously increasing despite the fact that only a small number of controlled trials dealing with either efficacy or safety of these natural products exist. So far, there are limited controlled evidences indicating the efficacy of TCM, such as aloe vera gel, wheat grass juice, Boswellia serrata, and bovine colostrum enemas in the management of patients with UC. Herbal medicine has always been considered to be preeminent among the various methods of healing within TCM, which is practiced extensively throughout clinics and hospitals in China alongside Western medicine.
There are numerous reports in the Chinese literature about the treatment of UC with herbal remedies, while only abstracts are available in English. It was noticeable that most of the respondents using herbal therapies believe that “natural” equates with “safe” and almost 30% of patients reported that such preparations cannot cause any harm. Herbs are dilute natural drugs containing many different chemicals, and their effects may be unpredictable. A few have been tested for their side effects, quality, or the potential for cross contamination by biological and chemical pollutants in the environments in which they are grown, transported, or sold.
Currently, TCM is widely used in the treatment of UC in Eastern Asian countries. Langmead et al has reported that herbal remedies for the treatment of IBD include slippery elm, fenugreek, devil’s claw, Mexican yam, tormentil, and Wei tong ning (a TCM).[16,17] Slippery elm, fenugreek, devil’s claw, tormentil, and Wei tong ning are novel drugs in the management of IBD. Chen et al reported that 118 cases of UC patients were treated with integration of TCM and that 86 cases of UC were treated with prednisone as controls. The therapeutic effects were observed and compared after two therapeutic courses of 40 consecutive days. As a result, there were 39 cases cured, 60 cases improved and 19 cases failed, with a total effective rate of 84% in TCM-treated group. In contrast, there were 15 cases cured, 37 cases improved and 34 cases failed, with a total effective rate of 60.5% in prednisone-treated group (P < 0.01). These data indicate that treatment of UC by the integrated TCM method is superior to that by simple Western drugs, such as prednisone and that it is also safe and effective in maintaining remission of UC.[16,18]
Aloe vera is a tropical plant used in traditional medicine throughout the world. It has been studied for its ability to relieve UC. Aloe vera gel is the mucilaginous aqueous extract of the leaf pulp of Aloe barbadensis Miller. Aloe vera juice has anti-inflammatory activity and been used by some doctors for patients with UC. It was the single most widely used herbal therapy. A double-blind, randomized trial was undertaken to examine the effectiveness and safety of aloe vera gel for the treatment of mild-to-moderate active UC. Thirty patients took 100 mL of oral aloe vera gel and 14 patients had 100 mL of a placebo twice daily for 4 weeks. Clinical remission, improvement, and response occurred in 9 (30%), 11 (37%), and 14 (47%), respectively, in aloe vera-treated patients compared with 1 (7%), 1 (7%), and 2 (14%), respectively, in controls. Although the numbers are small in this study, the number of patients who responded to aloe vera is more than those who took placebo. However, the numbers are similar to placebo responses in other trials and the placebo response rate is very low. The exact mechanisms of action of aloe vera are unclear. In vitro studies on human colonic mucosa have demonstrated that aloe vera gel could inhibit prostaglandin E2 and IL-8 secretion, indicating its role in antimicrobial and anti-inflammatory responses.
Boswellia or Indian frankincense is an ayurvedic herb that is derived from the resin of the plant, and has also been used traditionally to treat UC. Boswellic acid, the major constituent of Boswellia, is thought to contribute to most of the herbal pharmacologic activities. In vitro studies and animal models have shown that boswellic acid could inhibit 5-lipoxygenase selectively with anti-inflammatory and antiarthritic effects. Since the inflammatory process in IBD is associated with increased function of leukotrienes, the benefits of Boswellia in the treatment of UC have proven a positive result. Moreover, it has also been found to directly inhibit intestinal motility with a mechanism involving L-type Ca2+ channels. Boswellia has been found to reduce chemically induced edema and inflammation in the intestine in rodents. Other studies suggest that it has cytotoxic properties.
Gupta et al studied the treatment of 30 patients with chronic UC, and gave 20 patients a Boswellia gum preparation (900 mg daily divided into 3 doses for 6 weeks), and 10 patients sulfasalazine (3 gm daily divided into 3 doses for 6 weeks). They concluded that Boswellia was an effective treatment with few side effects, because 14 out of the 20 patients treated went into remission, and furthermore, 18 out of the 20 patients found an improvement in one or more parameters. In comparison, in the group taking sulfasalazine, 4 out of 10 went into remission, and 6 out of 10 showed improvement in one or more of the above parameters. In animal models of inflammation, it has been shown to be effective against Crohn’s disease, UC, and ileitis.
Butyrate is an important energy source for intestinal epithelial cells and plays a role in the maintenance of colonic homeostasis. Butyrate enemas have been studied for use in treating UC. Some studies have shown that the topical use of butyrate may help decrease the inflammation in the colon. Nancey et al proposed a possible explanation for the decreased oxidation in UC patients who showed that butyrate oxidation could be reduced by TNF-α at concentrations found in inflamed human mucosa. This anti-inflammatory effect of butyrate via NF-κB inhibition, contributing, for example, to decreased concentrations of myloperoxidase, cyclo-oxygenase-2, adhesion molecules, and different cytokine levels, has been confirmed in several in vitro and in vivo studies.[25,26] A diminished capacity of the intestinal mucosa to oxidize butyrate has been reported in patients with active UC. However, in patients with inactive UC a normal butyrate oxidation has been found in vivo, suggesting that in UC patients, abnormal butyrate oxidation is not a primary defect in colon mucosa. Administration of enteric-coated tablets (4 g of butyrate daily) in combination with mesalazine vs mesalazine alone significantly improved the disease activity score in patients with mild-to-moderate UC.
Licorice, which is derived from the root of the plant, is used extensively in TCM for a variety of conditions and ailments. Licorice has also got immune modulatory and adaptogenic property, which is required for the pathogenesis of UC. A number of active chemicals, including glycyrrhizin are thought to account for its biologic activity. Diammonium glycyrrhizinate is a substance that is extracted and purified from licorice, and may be useful in the treatment of UC. Evidence has also reported that diammonium glycyrrhizinate could improve intestinal mucosal inflammation in rats and, importantly, reduce expression of NF-κB, TNF-α, and ICAM-1 in inflamed mucosa. Clinical studies on licorice have also been performed in combination with other herbs and demonstrated to be effective in the management of UC. The antiestrogenic action documented for glycyrrhizin at high concentration has been associated with glycyrrhizin-binding estrogen receptors. However, estrogenic activity has also been reported for licorice and is attributed to its isoflavone constituents. It has been suggested that glycyrrhizin may exert its mineralocorticoid effect via an inhibition of 11b-hydroxysteroid dehydrogenase. Evidences have proven that glycyrrhizin could also suppress both plasma renin activity and aldosterone secretion. In addition, licorice has been shown to have chemopreventive effects through influencing Bcl-2/Bax and inhibiting carcinogenesis.[33–35]
Slippery elm (Ulmus fulva)
Slippery elm is a supplement that is made from the powdered bark of the slippery elm tree. It has long been used by Native Americans to treat cough, diarrhea, and other GI complaints. Recently, slippery elm has been studied for use as a supplement for IBD. A study has confirmed the antioxidant effects of slippery elm when used in patients with IBD. The research so far has been promising, but there is not enough to warrant the widespread use of slippery elm in the treatment of IBD.
Tormentil extracts have antioxidative properties and are used as a complementary therapy for chronic IBD. In individual patients with UC positive effects have been observed. Sixteen patients with active UC (clinical activity index ≥ 5) received tormentil extracts in escalating doses of 1200, 1800, 2400, and 3000 mg/day for 3 weeks each. Each treatment phase was followed by a 4-week washout phase. The outcome parameters were side effects, clinical activity index, C-reactive protein, and tannin levels in patient sera. Mild upper abdominal discomfort was experienced by 6 patients (38%), but did not require discontinuation of the medication. During therapy with 2400 mg of tormentil extracts per day, median clinical activity index, and C-reactive protein improved from 8 (6 to 10.75) and 8 (3 to 17.75) mg/L at baseline to 4.5 (1.75 to 6) and 3 (3 to 6) mg/L, respectively. During therapy, the clinical activity index decreased in all patients, whereas it increased during the washout phase. Neither undegraded nor metabolized tannins could be detected by liquid-mass spectrometry in sera. Tormentil extracts appeared safe up to 3000 mg/day.
The wheat grass (Triticum aestivum)
The wheat grass juice has been used for the treatment of various GI conditions. A double-blind study has demonstrated that supplementation with wheat grass juice for 1 month results in clinical improvement in 78% of people with UC, compared with 30% of those receiving a placebo. The amount of wheat grass used is 20 mL per day initially, and this is increased by 20 mL/day to a maximum of 100 mL per day (approximately 3.5 ounces). No serious side effects are noticed. Wheat grass juice appears to be effective and safe as a single or adjuvant treatment of active distal UC.
Curcumin is a compound in turmeric (Curcuma longa) that has been reported to have anti-inflammatory activity. It has been found to induce the flow of bile, which helps break down fats. Additionally, it could reduce the secretion of acid from the stomach and protect against injuries such as inflammation along the stomach (gastritis) or intestinal walls and ulcers from certain medications, stress, or alcohol. In a preliminary trial, 5 of 5 people with chronic ulcerative proctitis had an improvement in their disease after supplementing with curcumin. Curcumin inhibits the activation of NF-κB. NF-κB promotes the synthesis of many antioxidant enzymes. Curcumin directly binds to thioredoxin reductase and irreversibly changes its activity from an antioxidant to a strong pro-oxidant.
The amount of curcumin used was 550 mg twice a day for 1 month, followed by 550 mg 3 times a day for 1 month. Hanai and colleagues published the results of the first randomized, multicenter, double-blind, placebo-controlled trial from Japan to study curcumin‘s effect on UC maintenance. All 97 patients who enrolled and 89 patients who completed the study took a standard dose of mesalamine or sulfasalazine and either 1 g of curcumin or placebo twice daily for 6 months and then were followed for another 6 months off study medications. The relapse rate at 6 months on therapy was greater for the placebo group than for those who took curcumin (P = 0.049). Thus, curcumin may confer some additional therapeutic advantages when used in combination with conventional anti-inflammatory medications in UC.
Germinated barley foodstuff
Two open-label Japanese trials have shown the efficacy of Germinated barley foodstuff (GBF) in the treatment of UC, consisting mainly of dietary fiber and glutamine-rich protein that function as a probiotic.[41–44] In the first report, 11 patients given GBF for 4 weeks as an adjunctive treatment showed a greater decrease in clinical disease activity than 9 patients given conventional therapy alone. In a follow-up study, 24 weeks of treatment of 21 patients with GBF together with continuing 5-aminosalicylic acid and steroid therapy reduced rectal bleeding and nocturnal diarrhea. Adjunctive GBF also produced a lower relapse rate over 12 months when given to 22 patients with UC in remission than did conventional therapy in 37 patients. The potency of GBF on modulating microflora, as well as the high water-holding capacity, may play an important role in the treatment and prolongation of remission in UC.
Bromelain is an anti-inflammatory and has been used as a digestive aid and a blood thinner, as well as to treat sports injuries, sinusitis, arthritis, and swelling. Bromelain has been studied for use as a supplement for IBD, especially UC. Emerging research on pineapple suggests that pineapple’s “active” component, bromelain, may help relieve the inflammation associated with UC. The mechanisms that are primarily responsible for its anti-inflammatory effects are still unclear. However, proteolytic activity is required for the anti-inflammatory effect of bromelain on T-cell activation and cytokine secretion in vitro and in murine models of IBD in vivo.[46,47] The major mechanism of action of bromelain appears to be proteolytic in nature, although evidence also suggests an immunomodulatory and hormone-like activity acting via intracellular signaling pathways. Bromelain has been shown to reduce cell surface receptors, such as hyaluronan receptor CD44, which is associated with leukocyte migration and induction of pro-inflammatory mediators.[48,49] Additionally, bromelain is also reported to significantly reduce CD4+ T-cell infiltrations, which are primary effectors in animal models of inflammation in the gut. Bromelain has been found to be effective in improvement of clinical and histologic severity of colonic inflammation in a murine colitis model of IL-10-deficient mice. Previous work also reported clinical trial with bromelain in the treatment of mild UC. Although those 2 patients were unable to achieve remission on standard therapy, clinical and endoscopic evidence of improvement was documented.
Psyllium comes from a shrub-like herb called Plantago ovata and is classified as a mucilaginous fiber due to its gel-forming properties in water. It has a long history of use as a laxative as it absorbs water and expands as it travels through the digestive tract. The psyllium husk contains a largely insoluble fiber (hemicellulose), which helps to retain water within the bowel and effectively increases stool moisture content and weight. Soluble fibers (including psyllium) are noted for their effect on the stomach and small intestine, whereas insoluble fibers are noted for their effect on the large intestine, although some carbohydrates (such as psyllium) have an effect on both. Psyllium also has hypocholesterolemic effects, although the exact mechanism by which psyllium husk brings about a reduction of cholesterol is not totally clear. Animal studies have shown that psyllium increases the activity of cholesterol 7α-hydroxylase (a rate-limiting enzyme in bile acid synthesis, also referred to as cytochrome 7A) more than twice that of cellulose or oat bran, but less than cholestyramine. In animals fed a high-fat diet, psyllium could increase the activity of cholesterol 7α-hydroxylase and HMG-CoA reductase.
In a double-blind trial, patient with UC had a reduction in symptoms such as bleeding and remained in remission longer than those who took 20 g of ground psyllium seeds twice daily with water compared with those who were on the medication mesalazine alone.
There are many trials on herbal medicine for UC except mentioned above, which has good response. Withania somnifera, member of family Solanaceae, has good response in anti-inflammatory activity. Immunomodulatory role of W. somnifera roots and anti-inflammatory activity using adjuvant-induced arthritic rat models was also demonstrated. Considering the various biological activities, roots of W. somnifera can potentially be utilized for the effective treatment of various inflammatory conditions. Recently, Pawar et al studied that dose of the rectal gel applied at 1000 mg of WSRE (Withania somnifera root extract) per kg rat weight showed significant mucorestorative efficacy in the IBD-induced rats.
The present study analyzed the intestinal anti-inflammatory potential of oil-resin Copaifera langsdorffii (ORCL) and its diterpene constituent, kaurenoic acid (KA) in rat models of UC induced by acetic acid (AA-UC), and trinitribenzene sulfonic acid (TNBS-UC), and in indomethacin- and ischemia-reperfusion-induced intestinal inflammation (IND-II and I/R-II).
Plant tannins can help decrease the inflammation of UC patients. Patients with UC don’t have the protective benefit of normal mucin production, which can also leave them vulnerable to oxidized molecules increase the inflammation and mucosal injury seen in UC. The tannins appear to exert a protective effect against oxidative stress-induced cell death. Condensed tannins can also help return the GI flora to a state of balance. Patients with UC have GI flora that favor pathogenic bacteria. Current research with flavonoids and UC demonstrate a protective effect in mice treated with the colitis-inducing agent, dextran sulfate sodium, so as to prevent the occurrence of colitis. Green tea polyphenols have shown similar benefits in mice by attenuating colonic injury induced by experimental colitis.
Guggulsterone is a plant steroid found in the resin of the guggul plant, is an anti-inflammatory compound with the capacity to prevent and ameliorate T-cell–induced colitis. These data ground the use of GS, a natural cholesterol-lowering agent, in the treatment of chronic inflammatory diseases. Guggulsterone inhibits LPS- or IL-1b-induced ICAM-1 gene expression, NF-κB transcriptional activity, IκB phosphorylation/degradation, and NF-κB DNA-binding activity in IEC and strongly blocked IKK activity. Guggulsterone significantly reduced the severity of DSS-induced murine colitis as assessed by clinical disease activity score, colon length, and histology. Furthermore, tissue upregulation of IκB and IKK phosphorylation induced by DSS was attenuated in guggulsterone-treated mice. The guggulsterone derivative GG-52 has both protective and therapeutic effects on inflammation in the colon, indicating that it has a potential clinical value for the treatment of IBD.
There is small clinical study with 21 ulcerative colitis and Crohn’s disease patients showed a proprietary extract of Agaricus subrufescens (agaricus blazei) had an anti-inflammatory effect. Xu et al. found the therapeutic effect of herb-partitioned spread moxibustion for treatment of chronic nonspecific UC is better than that of the oral administration of sulfasalazine with less adverse reaction. Sixty cases were randomly divided into a spread moxibustion group (n = 28) and a western medicine group (n = 32). The cured-markedly effective rate was 71.4% (20/28) in the spread moxibustion group, and 25.0% (8/32) in the western medicine group.
A new herbal drug Fufangkushen colon-coated (FCC) capsule, is effective and safe in the treatment of active UC. In the double-blind, double-dummy, multicenter, randomized, and controlled study, 320 active UC patients with TCM pattern of damp–heat accumulating in the interior were assigned to 2 groups: 240 treated with FCC plus HD placebo treatment, 80 with HD plus FCC placebo. At the 8th week, 72.50% of patients in FCC group (170 of 234) and 65.00% of patients in HD group (52 of 80) had achieved a clinical response. One of the Chinese herbal suppository named Qingchang Shuan is commonly used for the treatment of UC. It has the effects of clearing away heat and toxic materials, and promoting tissue regeneration by removing blood stasis.
Although many of these herbs seem to be effective in the management of UC based on clinical experiences, the long-term efficacies of these herbal medicines need further investigation.
UC is a chronic medical condition that may require patients to take medication throughout their lives to prevent relapse, reduce the risk of colorectal cancer and improve quality of life. Although patients at all stages of UC are affected by nonadherence, those in symptomatic remission are particularly at risk for poor adherence, often taking less than 70% of their prescribed medication.[9,10,51] Herbal medicine remedies are able to treat a wide range of acute and chronic GI disorders, including UC. Herbals mentioned above represent a simple paradigm of what is in regular use by patients with UC in many countries of the world. Physicians should address their patients straightforwardly regarding this kind of treatment and offer evidence-based information about their use. At the same time, large clinical double-blind studies assessing the most commonly used alternative therapies are needed. These herbal medicines have often been tested in their traditional context and have also been found to be useful in novel and exciting ways, thereby opening up new avenues for the treatment of pathologic states. Most herbal medicines undergo a similar level of rigorous testing as pharmaceutical medicines and there are positive examples of successful biochemical, animal model, and human-controlled trials within the literature. As a result, the manufacture, marketing, and prescribing of herbal medicines is now at an unprecedented level and is expected to continue to grow. Many herbal medicines are effective when used as therapeutic agents in treating illness and disease. Thus, herbal medicine is one of the great medical systems of the world, with an unbroken tradition dating back to the third century BC.
Saudi J Gastroenterol. 2012 Jan-Feb; 18(1): 3–10.
Copyright : © Saudi Journal of Gastroenterology
Fei Ke, Praveen Kumar Yadav,1 and Liu Zhan Ju1
Department of Surgery, The Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
1Department of Gastroenterology, The Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Address for correspondence: Dr. Liu Zhan Ju, Department of Gastroenterology, The Shanghai Tenth People’s Hospital, Tongji University, No. 301 Yanchang Road, Shanghai-200 072, China. E-mail: firstname.lastname@example.org
This work is supported by the Grants from the National Natural Science Foundation of China (no. 30971358, 81061120521).
Source of Support: The Grants from the National Natural Science Foundation of China (no. 30971358, 81061120521)
Conflict of Interest: None declared.
- Other Sections▼
1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–29. [PubMed]
2. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–40. [PubMed]
3. Liu ZJ, Yadav PK, Su JL, Wang JS, Fei K. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2009;15:5784–8. [PMC free article] [PubMed]
4. Loftus EV., Jr Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17. [PubMed]
5. Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology. 2003;125:1583–90. [PubMed]
6. Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8–15. [PubMed]
7. Wang Y, Ouyang Q. Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients. J Gastroenterol Hepatol. 2007;22:1450–5. [PubMed]
8. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577–85. [PubMed]
9. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929–33. [PubMed]
10. Cerveny P, Bortlik M, Kubena A, Vlcek J, Lakatos PL, Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis. 2007;13:1244–9. [PubMed]
11. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535–44. [PubMed]
12. Yadav PK, Liu Z. Current strategies for the treatment of ulcerative colitis. Recent Pat Inflamm Allergy Drug Discov. 2009;3:65–72. [PubMed]
13. Comar KM, Kirby DF. Herbal remedies in gastroenterology. J Clin Gastroenterol. 2005;39:457–68. [PubMed]
14. Tillisch K. Complementary and alternative medicine for gastrointestinal disorders. Clin Med. 2007;7:224–7. [PubMed]
15. D’Inca R, Garribba AT, Vettorato MG, Martin A, Martines D, Di Leo V, et al. Use of alternative and complementary therapies by inflammatory bowel disease patients in an Italian tertiary referral centre. Dig Liver Dis. 2007;39:524–9. [PubMed]
16. Langmead L, Rampton DS. Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2006;23:341–9. [PubMed]
17. Langmead L, Makins RJ, Rampton DS. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther. 2004;19:521–7. [PubMed]
18. Chen Q, Zhang H. Clinical study on 118 cases of ulcerative colitis treated by integration of traditional Chinese and Western medicine. J Tradit Chin Med. 1999;19:163–5. [PubMed]
19. Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis. 2002;8:174–9. [PubMed]
20. Dahmen U, Gu YL, Dirsch O, Fan LM, Li J, Shen K, et al. Boswellic acid, a potent antiinflammatory drug, inhibits rejection to the same extent as high dose steroids. Transplant Proc. 2001;33:539–41. [PubMed]
21. Frank MB, Yang Q, Osban J, Azzarello JT, Saban MR, Saban R, et al. Frankincense oil derived from Boswellia carteri induces tumor cell specific cytotoxicity. BMC Complement Altern Med. 2009;9:6. [PMC free article] [PubMed]
22. Gupta I, Parihar A, Malhotra P, Gupta S, Lüdtke R, Safayhi H, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med. 2001;67:391–5. [PubMed]
23. Krieglstein CF, Anthoni C, Rijcken EJ, Laukötter M, Spiegel HU, Boden SE, et al. Acetyl-11-keto-betaboswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis. 2001;16:88–95. [PubMed]
24. Nancey S, Moussata D, Graber I, Claudel S, Saurin JC, Flourié B. Tumor necrosis factor alpha reduces butyrate oxidation in vitro in human colonic mucosa: A link from inflammatory process to mucosal damage? Inflamm Bowel Dis. 2005;11:559–66. [PubMed]
25. Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, et al. Butyrate inhibits inflammatory B inhibition: implications for Crohn’s disease. Gut. 2000;47:397–403. [PMC free article] [PubMed]
26. Song M, Xia B, Li J. Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1b, and nuclear factor kB in trinitrobenzene sulphonic acid induced colitis in rats. Postgrad Med J. 2006;82:130–5. [PMC free article] [PubMed]
27. Kato K, Ishii Y, Mizuno S, Sugitani M, Asai S, Kohno T, et al. Usefulness of rectally administering [1-13C]-butyrate for breath test in patients with active and quiescent ulcerative colitis. Scand J Gastroenterol. 2007;42:207–14. [PubMed]
28. Simpson EJ, Chapman MA, Dawson J, Berry D, Macdonald IA, Cole A. In vivo measurement of colonic butyrate metabolism in patients with quiescent ulcerative colitis. Gut. 2000;46:73–7. [PMC free article] [PubMed]
29. Vernia P, Monteleone G, Grandinetti G, Villotti G, Di Giulio E, Frieri G, et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo- controlled pilot study. Dig Dis Sci. 2000;45:976–81. [PubMed]
30. Kudo T, Okamura S, Zhang Y, Masuo T, Mori M. Topical application of glycyrrhizin preparation ameliorates experimentally induced colitis in rats. World J Gastroenterol. 2011;17:2223–8. [PMC free article] [PubMed]
31. Yuan H, Ji WS, Wu KX, Jiao JX, Sun LH, Feng YT. Anti-inflammatory effects of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. World J Gastroenterol. 2006;12:4578–81. [PubMed]
32. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Treatment of functional dyspepsia with a herbal preparation.A double-blind, randomized, placebo-controlled, multicenter trial. Digestion. 2004;69:45–52. [PubMed]
33. Somjen D, Knoll E, Vaya J, Stem N, Tamir S. Estrogen-like activity of licorice root constituents: glabridin and glabrene, in vascular tissues in vitro and in vivo. J Steroid Biochem Mol Biol. 2004;91:147–55. [PubMed]
34. Jo EH, Hong HD, Ahn NC, Jung JW, Yang SR, Park JS, et al. Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell. J Agric Food Chem. 2004;52:1715–9. [PubMed]
35. Takahashi T, Takasuka N, Iigo M, Baba M, Nishino H, Tsuda H, et al. Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development. Cancer Sci. 2004;95:448–53. [PubMed]
36. Langmead L, Dawson C, Hawkins C, Banna N, Loo S, Rampton DS. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: An in vitro study. Aliment Pharmacol Ther. 2002;16:197–205. [PubMed]
37. Huber R, Ditfurth AV, Amann F, Güthlin C, Rostock M, Trittler R, et al. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol. 2007;41:834–8. [PubMed]
38. Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol. 2002;37:444–9. [PubMed]
39. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50:2191–3. [PubMed]
40. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:1502–6. [PubMed]
41. Araki Y, Andoh A, Fujiyama Y, Kanauchi O, Takenaka K, Higuchi A, et al. Germinated barley foodstuff exhibits different adsorption properties for hydrophilic versus hydrophobic bile acids. Digestion. 2001;64:248–54. [PubMed]
42. Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol. 2002;17:818–24. [PubMed]
43. Fukuda M, Kanauchi O, Araki Y, Andoh A, Mitsuyama K, Takagi K, et al. Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med. 2002;9:65–70. [PubMed]
44. Kanauchi O, Suga T, Tochihara M, Hibi T, Naganuma M, Homma T, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol. 2002;37(Suppl 14):67–72. [PubMed]
45. Hanai H, Kanauchi O, Mitsuyama K, Andoh A, Takeuchi K, Takayuki I, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med. 2004;13:643–7. [PubMed]
46. Mynott TL, Crossett B, Prathalingam SR. Proteolytic inhibition of Salmonella enterica serovar typhimurium-induced activation of the mitogen-activated protein kinases ERK and JNK in cultured human intestinal cells. Infect Immun. 2002;70:86–95. [PMC free article] [PubMed]
47. Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol. 2002;104:183–90. [PubMed]
48. Manhart N, Akomeah R, Bergmeister H, Spittler A, Ploner M, Roth E. Administration of proteolytic enzymes bromelain and trypsin diminish the number of CD4+ cells and the interferon-gamma response in Peyer’s patches and spleen in endotoxemic balb/c mice. Cell Immunol. 2002;215:113–9. [PubMed]
49. Hale LP, Greer PK, Trinh CT, Gottfried MR. Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease. Clin Immunol. 2005;116:135–42. [PubMed]
50. Kane S, Goldberg MJ. Use of bromelain for mild ulcerative colitis. Ann Intern Med. 2000;132:680. [PubMed]
51. Blackwood AD, Salter J, Dettmar PW, Chaplin MF. Dietary fibre, physicochemical properties and their relationship to health. J R Soc Promot Health. 2000;120:242–7. [PubMed]
52. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191–8. [PubMed]
53. Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU) Am J Gastroenterol. 1999;94:427–33. [PubMed]
54. Rasool M, Varalakshmi P. Immunomodulatory role of Withania somnifera root powder on experimentally induced inflammation: An in vivo and in vitro study. Vascul Pharmacol. 2006;44:406–10. [PubMed]
55. Pawar P, Gilda S, Sharma S, Jagtap S, Paradkar A, Mahadik K, et al. Rectal gel application of Withania somnifera root extract expounds anti-inflammatory and mucorestorative activity in TNBS-induced Inflammatory Bowel Disease. BMC Complement Altern Med. 2011;11:34. [PMC free article] [PubMed]
56. Farias P, Laura A. Studies on the anti-inflammatory potential of copaiba oil-resin from copaifera langsdorffii and its diterpene constituent kaurenoic acid in experimental models of intestinal inflammation. [Last accessed on 2011 Jul 7]. Available from: http://www.openthesis.org/documents/Studies-antiinflammatory-potential-copaiba-332041.html .
57. Spencer JP, Schroeter H, Rechner AR, Rice-Evans C. Bioavailability of flavan-3-ols and procyanidins: Gastrointestinal tract influences and their relevance to bioactive forms in vivo. Antioxid Redox Signal. 2001;3:1023–39. [PubMed]
58. Sartor RB. Microbial-host interactions in inflammatory bowel diseases and experimental colitis. Nestle Nutr Workshop Ser Pediatr Program. 2009;64:121–37. discussion 132-7, 251-7.
59. Oz HS, Chen TS, McClain CJ, de Villiers WJ. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem. 2005;16:297–304. [PubMed]
60. Mazzon E, Muià C, Paola RD, Genovese T, Menegazzi M, De Sarro A, et al. Green tea polyphenol extract attenuates colon injury induced by experimental colitis. Free Radic Res. 2005;39:1017–25. [PubMed]
61. Mencarelli A, Renga B, Palladino G, Distrutti E, Fiorucci S. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. Biochem Pharmacol. 2009;78:1214–23. [PubMed]
62. Cheon JH, Kim JS, Kim JM, Kim N, Jung HC, Song IS. Plant sterol guggulsterone Inhibits nuclear Factor-κB Signaling in Intestinal Epithelial Cells by Blocking IkB Kinase and ameliorates acute murine colitis. Inflamm Bowel Dis. 2006;12:1152–61. [PubMed]
63. Kim JM, Kang HW, Cha MY, Yoo D, Kim N, Kim IK, et al. Novel guggulsterone derivative GG-52 inhibits NF-kB signaling in intestinal epithelial cells and attenuates acute murine colitis. Lab Invest. 2010;90:1004–15. [PubMed]
64. Førland DT, Johnson E, Saetre L, Lyberg T, Lygren I, Hetland G. Effect of an extract based on the medicinal mushroom Agaricus blazei Murill on expression of cytokines and calprotectin in patients with ulcerative colitis and Crohn’s disease. Scand J Immunol. 2011;73:66–75. [PubMed]
65. Xu YL, Du YH, Xu XM, He TY. Observation on therapeutic effect of herb-partitioned spread moxibustion for treatment of chronic nonspecific ulcerative colitis. Zhongguo Zhen Jiu. 2010;30:289–91. [PubMed]
66. Gong Y, Zha Q, Li L, Liu Y, Yang B, Liu L, et al. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: A double-blinded and randomized study. J Ethnopharmacol. 2011 [In Press]
67. Dai YC, Tang ZP, Ma GT, Gong YP, Liu W, Zhang YL. A review of Qingchang Shuan for treatment of ulcerative colitis. J Tradit Chin Med. 2010;30:237–40. [PubMed]
Articles from Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association are provided here courtesy of